| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, CEO and Director
1 company
Daniel M Schmitt is President, CEO and Director at ACTU. Daniel M Schmitt's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $155K at current prices.
Net of sales, the ACTU filings show accumulation of 140,844 shares.
Daniel M Schmitt has 6 Form 4 filings on record from August 2024 to October 2026, all as President, CEO and Director at Actuate Therapeutics, Inc. Common stock (ACTU), 2024–2026.
The 10 reported transactions were 4 option or other derivative awards, 2 open-market purchases, 2 option exercises and 2 tax withholdings.
Counted by filing, the open-market trades come to 1 purchase worth about $50K and no sales.
The only open-market purchase was 140,844 shares of ACTU at an average $0.35 on October 28, 2026, about $50K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | ACTU Actuate Therapeutics, Inc. Common Stock | President, CEO and Director | Buy | 140,844 | $0.36 | $49,999.62 | +46.7% | - | - |